MEXICO CITY, Nov. 28, 2022 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, announces a leadership succession plan that positions the Company to continue driving profitable growth and delivering on the Company's vision, as CEO Jorge Brake has informed the Board of his intention to transition from the CEO role while maintaining active involvement in the Company's future. Mr. Brake will be appointed Active Vice Chairman of the Board of Directors, pending approval at Genomma's next Annual General Shareholders Meeting to be held in April 2023.
- In accordance with the Company's leadership succession plan, Mr. Rodrigo Herrera, Chairman of the Board informs that Marco Sparvieri, currently Genomma Lab's Chief Operating Officer, will succeed Jorge Brake as Chief Executive Officer.
- Genomma's succession plan ensures a six month transition period during which Mr.
- With a strong foundation and clear trajectory in place, now is the right time to implement our succession plan," said Brake.
- Mr. Sparvieri joined Genomma Lab in 2014 after a successful 20 year career with Procter & Gamble, working in several geographies and roles.